A Unique New Fertility Treatment
Don't hesitate to comment below if you have any questions or additional phrases
INVOBioscience A
Unique New
Fertility Treatment June 2009
,
Forward Looking Statement This release includes forward-looking statements within the meaning of
Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov.
We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
,
Stock Overview (as of 6/18/09)
Exchange:
OTC BB Symbol: IVOB Recent Price: $.15
Market Cap: $8.2M 52
Week Range: $.05- $5
.50 Shares Outstanding: 53.7 M Approximate
Float: 14 M
,
Introduction INVO Bioscience went public via a reverse merger in
December 2008. INVO began trading under the
symbol IVOB in
February 2009.
INVO is introducing a new device for Intra-vaginal culture to the infertility market. This is a fertility treatment similar to In-vitro Fertilization (
IVF) but simpler to perform and can be made more available to the infertile population worldwide reaching patients that cannot currently be treated by traditional IVF. The procedure may be provided without an IVF center and therefore can be available in many more locations than IVF. INVO is well positioned to capture a significant share of the unmet market needs. ,Un-addressed Infertility
150 million infertile couples worldwide (
ESHRE 2007)
1 million technological procedures that help infertile couples to conceive have been performed worldwide
Less than .5% are treated with and average of 2+ cycles per couple Over 149 million infertile couples go untreated, this is the population INVO is targeting
Reasons for lack of treatment Cost
Availability
Awareness ,INVO Bioscience
Goal Reach the unmet needs of the Infertility population through providing A unique new fertility treatment
A geographically available treatment A less expensive treatment A more natural treatment ,
Market Strategy INVO Bioscience is not competing with IVF
INVO allows IVF clinics to open low cost INVO centers to expand their geographical reach, increase their business and treat infertile couples who could not be treated before Lower cost will allow patients to go directly to INVO vs. starting with
IUI treatment ( low efficacy)
Offers a couple a more natural option to traditional IVF ,INVO
Procedure During the INVO procedure fertilization and embryo development occur inside the woman’s vaginal cavity in a disposable single use device which is called the INVOcell. (This device holds the eggs, sperm and culture medium)
In the INVO procedure either mild ovarian stimulation or no ovarian stimulation are used. Using a mild stimulation protocol, 1-10 oocytes are retrieved under light sedation. The INVOcell is then placed in the patient’s vaginal cavity for an incubation period